Elucidation of the underlying mechanism of Hua-ban decoction in alleviating acute lung injury by an integrative approach of network pharmacology and experimental verification
Molecular Immunology · 2023
DOI: 10.1016/j.molimm.2023.02.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Immunology, 2023. Verfasst von Wei Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Respiratory Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, China. Hauptthemen laut MEDLINE: Tumor Necrosis Factor-alpha, Acute Lung Injury. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The pathogenic hyper-inflammatory response has been regarded as the major cause of the severity and death related to acute lung injury (ALI). Hua-ban decoction (HBD) is a classical prescription in traditional Chinese medicine (TCM). It has been extensively used to treat inflammatory diseases; however, its bioactive components and therapeutic mechanisms remain unclear. Here, we established a lipopolysaccharide (LPS)-induced ALI model that presents a hyperinflammatory process to explore the pharmaco-dynamic effect and underlying molecular mechanism of HBD on ALI. In vivo, we confirmed that in LPS-induced ALI mice, HBD improved pulmonary injury by via down-regulating the expression of proinflammatory cytokines, including IL-6, TNF-α, and macrophage infiltration, as well as macrophage M1 polarization. Moreover, in vitro experiments in LPS-stimulated macrophages demonstrated that the potential bioactive compounds of HBD inhibited the secretion of IL-6 and TNF-α. Mechanically, the data revealed that HBD treatment of LPS-induced ALI acted via NF-κB pathway, which regulated macrophage M1 polarization. Additionally, two major HBD compounds, i.e., quercetin and kaempferol, showed a high binding affinity with p65 and IkBα. In conclusion, the data obtained in this study demonstrated the therapeutic effects of HBD, which indicates the possibility for the development of HBD as a potential treatment for ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Respiratory Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, China.
- Clinical Medicine Center, Long hua Hospital, Shanghai University of Traditional Chinese Medicine, China.
- Institute of Respiratory Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, China. Electronic address: zhangshaoyan000@163.com.
- Institute of Respiratory Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, China. Electronic address: Dr_luzh@shutcm.edu.cn.
Zitieren
APA
Zhou, W., Hu, Z., Wu, X., Zhang, S., Jiang, Y., Tian, L., Huang, X., Ma, Z., Qiu, L., Zheng, P., Zhang, S., & Lu, Z. (2023). Elucidation of the underlying mechanism of Hua-ban decoction in alleviating acute lung injury by an integrative approach of network pharmacology and experimental verification. Molecular Immunology. https://doi.org/10.1016/j.molimm.2023.02.013
Vancouver
Zhou W, Hu Z, Wu X, Zhang S, Jiang Y, Tian L, et al. Elucidation of the underlying mechanism of Hua-ban decoction in alleviating acute lung injury by an integrative approach of network pharmacology and experimental verification. Molecular Immunology. 2023. doi:10.1016/j.molimm.2023.02.013
BibTeX
@article{Zhou2023,
author = {Zhou, Wei and Hu, Zhuannan and Wu, Xianwei and Zhang, Shunxian and Jiang, Yuwei and Tian, Li and Huang, Xing and Ma, Zifeng and Qiu, Lei and Zheng, Peiyong and Zhang, Shaoyan and Lu, Zhenhui},
title = {Elucidation of the underlying mechanism of Hua-ban decoction in alleviating acute lung injury by an integrative approach of network pharmacology and experimental verification},
journal = {Molecular Immunology},
year = {2023},
doi = {10.1016/j.molimm.2023.02.013}
}
EUVIMED